All Posts: next generation sequencing testing
-
Rise in Claim Denial Rates for Cancer-Related Advanced Genetic Testing
A newly published analysis by Georgetown Lombardi member So-Yeon Kang, PhD, MBA, and colleagues has found that both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national coverage determination that established coverage standards for NGS testing. Read more about this research.
Category: News Release